Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved

1.

Boutari C, DeMarsilis A, Mantzoros CS. Obesity and diabetes. Diabetes Res Clin Pract. 2023;202(110773). https://doi.org/10.1016/j.diabres.2023.110773.

2.

Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077–93.CrossRef

3.

Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, Bennett JE, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–50.CrossRef

4.

Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev. 2014;15(6):504–15.PubMedPubMedCentralCrossRef

5.

Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89(3):309–19. https://doi.org/10.1016/j.diabres.2010.04.012.CrossRefPubMed

6.

Jayedi A, Soltani S, Motlagh SZ-t, Emadi A, Shahinfar H, Moosavi H, et al. Anthropometric and adiposity indicators and risk of type 2 diabetes: systematic review and dose-response meta-analysis of cohort studies. Bmj. 2022;376(e067516). https://doi.org/10.1136/bmj-2021-067516.

7.

Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126(11):1477–500. https://doi.org/10.1161/circresaha.120.316101.CrossRefPubMed

8.

Michaelidou M, Pappachan JM, Jeeyavudeen MS. Management of diabesity: Current concepts. World J Diabetes. 2023;14(4):396–411. https://doi.org/10.4239/wjd.v14.i4.396.CrossRefPubMedPubMedCentral

9.

Frontera WR, Ochala J. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int. 2015;96(3):183–95. https://doi.org/10.1007/s00223-014-9915-y.CrossRefPubMed

10.

Murray B, Rosenbloom C. Fundamentals of glycogen metabolism for coaches and athletes. Nutr Rev. 2018;76(4):243–59.PubMedPubMedCentralCrossRef

11.

DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 1981;30(12):1000–7. https://doi.org/10.2337/diab.30.12.1000.CrossRefPubMed

12.

Zurlo F, Larson K, Bogardus C, Ravussin E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Investig. 1990;86(5):1423–7.PubMedPubMedCentralCrossRef

13.

Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–65. https://doi.org/10.1038/nrendo.2012.49.CrossRefPubMed

14.

Argilés JM, Campos N, Lopez-Pedrosa JM, Rueda R, Rodriguez-Mañas L. Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J Am Med Dir Assoc. 2016;17(9):789–96.PubMedCrossRef

15.

Pileggi CA, Parmar G, Harper M-E. The lifecycle of skeletal muscle mitochondria in obesity. Obes Rev. 2021;22(5):e13164. https://doi.org/10.1111/obr.13164.CrossRefPubMed

16.

Blüher M. Metabolically healthy obesity. Endocrine Reviews. 2020;41(3):bnaa004. https://doi.org/10.1210/endrev/bnaa004.CrossRefPubMedPubMedCentral

17.

Izzo A, Massimino E, Riccardi G, Della PG. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. 2021;13(1):183.PubMedPubMedCentralCrossRef

18.

Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, De Rekeneire N, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009;32(11):1993–7.PubMedPubMedCentralCrossRef

19.

Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010;33(7):1497–9.PubMedPubMedCentralCrossRef

20.

Andersen H, Nielsen S, Mogensen CE, Jakobsen J. Muscle strength in type 2 diabetes. Diabetes. 2004;53(6):1543–8. https://doi.org/10.2337/diabetes.53.6.1543.CrossRefPubMed

21.

Anagnostis P, Gkekas NK, Achilla C, Pananastasiou G, Taouxidou P, Mitsiou M, et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: a systematic review and meta-analysis. Calcif Tissue Int. 2020;107:453–63.PubMedCrossRef

22.

Choi SJ, Files DC, Zhang T, Wang Z-M, Messi ML, Gregory H, et al. Intramyocellular lipid and impaired myofiber contraction in normal weight and obese older adults. J Gerontol: Ser A. 2015;71(4):557–64. https://doi.org/10.1093/gerona/glv169.CrossRef

23.

Smeuninx B, McKendry J, Wilson D, Martin U, Breen L. Age-related anabolic resistance of myofibrillar protein synthesis is exacerbated in obese inactive individuals. J Clin Endocrinol Metab. 2017;102(9):3535–45. https://doi.org/10.1210/jc.2017-00869.CrossRefPubMedPubMedCentral

24.

Hulens M, Vansant G, Lysens R, Claessens AL, Muls E, Brumagne S. Study of differences in peripheral muscle strength of lean versus obese women: an allometric approach. Int J Obes. 2001;25(5):676–81. https://doi.org/10.1038/sj.ijo.0801560.CrossRef

25.

Tomlinson DJ, Erskine RM, Morse CI, Winwood K, Onambélé-Pearson G. The impact of obesity on skeletal muscle strength and structure through adolescence to old age. Biogerontology. 2016;17(3):467–83. https://doi.org/10.1007/s10522-015-9626-4.CrossRefPubMed

26.

Tomlinson DJ, Erskine RM, Morse CI, Winwood K, Onambélé-Pearson GL. Combined effects of body composition and ageing on joint torque, muscle activation and co-contraction in sedentary women. Age (Dordr). 2014;36(3):9652. https://doi.org/10.1007/s11357-014-9652-1.CrossRefPubMedPubMedCentral

27.

MÅrin P, Andersson B, Krotkiewski M, Björntorp P. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care. 1994;17(5):382–6.PubMedCrossRef

28.

Oberbach A, Bossenz Y, Lehmann S, Niebauer J, Adams V, Paschke R, et al. Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care. 2006;29(4):895–900.PubMedCrossRef

29.

Gaster M, Staehr P, Beck-Nielsen H, Schrøder HD, Handberg A. GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? Diabetes. 2001;50(6):1324–9.PubMedCrossRef

30.

Frankenberg NT, Mason SA, Wadley GD, Murphy RM. Skeletal muscle cell-specific differences in type 2 diabetes. Cell Mol Life Sci. 2022;79(5):256.PubMedPubMedCentralCrossRef

31.

Helge JW, Fraser AM, Kriketos AD, Jenkins AB, Calvert GD, Ayre KJ, et al. Interrelationships between muscle fibre type, substrate oxidation and body fat. Int J Obes. 1999;23(9):986–91. https://doi.org/10.1038/sj.ijo.0801030.CrossRef

32.

Kriketos AD, Pan DA, Lillioja S, Cooney GJ, Baur LA, Milner MR, et al. Interrelationships between muscle morphology, insulin action, and adiposity. Am J Physiol. 1996;270(6 Pt 2):R1332–9. https://doi.org/10.1152/ajpregu.1996.270.6.R1332.CrossRefPubMed

33.

Tanner CJ, Barakat HA, Dohm GL, Pories WJ, MacDonald KG, Cunningham PR, et al. Muscle fiber type is associated with obesity and weight loss. Am J Physiol Endocrinol Metab. 2002;282(6):E1191–6. https://doi.org/10.1152/ajpendo.00416.2001.CrossRefPubMed

34.

Zierath J, He L, Guma A, Wahlström EO, Klip A, Wallberg-Henriksson H. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia. 1996;39:1180–9.PubMedCrossRef

35.

Groen BB, Hamer HM, Snijders T, Van Kranenburg J, Frijns D, Vink H, et al. Skeletal muscle capillary density and microvascular function are compromised with aging and type 2 diabetes. J Appl Physiol. 2014;116(8):998–1005.PubMedCrossRef

36.

Benedict KF, Coffin GS, Barrett EJ, Skalak TC. Hemodynamic systems analysis of capillary network remodeling during the progression of type 2 diabetes. Microcirculation. 2011;18(1):63–73.PubMedCrossRef

37.

de Jongh RT, Serné EH, Ijzerman RG, de Vries G, Stehouwer CDA. Impaired microvascular function in obesity. Circulation. 2004;109(21):2529–35. https://doi.org/10.1161/01.CIR.0000129772.26647.6F.CrossRefPubMed

38.

Vinet A, Karpoff L, Walther G, Startun A, Obert P, Goret L, et al. Vascular reactivity at rest and during exercise in middle-aged obese men: effects of short-term, low-intensity, exercise training. Int J Obes. 2011;35(6):820–8. https://doi.org/10.1038/ijo.2010.206.CrossRef

39.

Bosma M. Lipid droplet dynamics in skeletal muscle. Exp Cell Res. 2016;340(2):180–6. https://doi.org/10.1016/j.yexcr.2015.10.023.CrossRefPubMed

40.

de Almeida ME, Nielsen J, Petersen MH, Wentorf EK, Pedersen NB, Jensen K, et al. Altered intramuscular network of lipid droplets and mitochondria in type 2 diabetes. Am J Physiol-Cell Physiol. 2023;324(1):C39–57.PubMedCrossRef

41.

Daemen S, Gemmink A, Brouwers B, Meex RC, Huntjens PR, Schaart G, et al. Distinct lipid droplet characteristics and distribution unmask the apparent contradiction of the athlete’s paradox. Molecular metabolism. 2018;17:71–81.PubMedPubMedCentralCrossRef

42.

van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav. 2008;94(2):231–41. https://doi.org/10.1016/j.physbeh.2007.11.049.CrossRefPubMed

43.

Engin AB. What is lipotoxicity? Obesity and lipotoxicity. 2017. 197–220. https://doi.org/10.1007/978-3-319-48382-5_8.

44.

Berria R, Wang L, Richardson DK, Finlayson J, Belfort R, Pratipanawatr T, et al. Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol-Endocrinol Metab. 2006;290(3):E560–5. https://doi.org/10.1152/ajpendo.00202.2005.CrossRefPubMed

45.

Tam CS, Covington JD, Bajpeyi S, Tchoukalova Y, Burk D, Johannsen DL, et al. Weight gain reveals dramatic increases in skeletal muscle extracellular matrix remodeling. J Clin Endocrinol Metab. 2014;99(5):1749–57. https://doi.org/10.1210/jc.2013-4381.CrossRefPubMedPubMedCentral

46.

Nesti L, Pugliese NR, Sciuto P, Natali A. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19(1):134. https://doi.org/10.1186/s12933-020-01109-1.CrossRefPubMedPubMedCentral

47.

Petersen MC, Smith GI, Palacios HH, Farabi SS, Yoshino M, Yoshino J, et al. Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity. Cell Metab. 2024;36(4):745-61.e5. https://doi.org/10.1016/j.cmet.2024.03.002.CrossRefPubMed

48.

Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Investig. 2019;129(10):3978–89.PubMedPubMedCentralCrossRef

49.

Baum T, Cordes C, Dieckmeyer M, Ruschke S, Franz D, Hauner H, et al. MR-based assessment of body fat distribution and characteristics. Eur J Radiol. 2016;85(8):1512–8. https://doi.org/10.1016/j.ejrad.2016.02.013.CrossRefPubMed

50.

Schulze MB, Stefan N. Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications. Nat Rev Endocrinol. 2024;20(11):633–46.PubMedCrossRef

51.

Lopez-Pedrosa JM, Camprubi-Robles M, Guzman-Rolo G, Lopez-Gonzalez A, Garcia-Almeida JM, Sanz-Paris A, et al. The vicious cycle of type 2 diabetes mellitus and skeletal muscle atrophy: clinical, biochemical, and nutritional bases. Nutrients. 2024;16(1):172.PubMedPubMedCentralCrossRef

52.

James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. 2021;22(11):751–71. https://doi.org/10.1038/s41580-021-00390-6.CrossRefPubMed

53.

Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, et al. Insulin-sensitive obesity. Am J Physiol-Endocrinol Metab. 2010;299(3):E506–15.PubMedCrossRef

54.

Gustafson B, Hedjazifar S, Gogg S, Hammarstedt A, Smith U. Insulin resistance and impaired adipogenesis. Trends Endocrinol Metab. 2015;26(4):193–200.PubMedCrossRef

55.

Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56(4):901–11. https://doi.org/10.2337/db06-0911.CrossRefPubMed

56.

Caselli C. Role of adiponectin system in insulin resistance. Mol Genet Metab. 2014;113(3):155–60. https://doi.org/10.1016/j.ymgme.2014.09.003.CrossRefPubMed

57.

Castela I, Morais J, Barreiros-Mota I, Silvestre MP, Marques C, Rodrigues C, et al. Decreased adiponectin/leptin ratio relates to insulin resistance in adults with obesity. Am J Physiol-Endocrinol Metab. 2023;324(2):E115–9. https://doi.org/10.1152/ajpendo.00273.2022.CrossRefPubMed

58.

Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91. https://doi.org/10.1126/science.7678183.CrossRefPubMed

59.

Gutierrez-Rodelo C, Arellano-Plancarte A, Hernandez-Aranda J, Landa-Galvan HV, Parra-Mercado GK, Moreno-Licona NJ, et al. Angiotensin II inhibits insulin receptor signaling in adipose cells. Int J Mol Sci. 2022;23(11):6048.PubMedPubMedCentralCrossRef

60.

Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol. 2013;4:71.CrossRef

61.

Khan IM, Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes. 2015;39(11):1607–18. https://doi.org/10.1038/ijo.2015.104.CrossRef

62.

Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction*. J Biol Chem. 1997;272(2):971–6. https://doi.org/10.1074/jbc.272.2.971.CrossRefPubMed

63.

Frigolet ME, Torres N, Tovar AR. The renin–angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem. 2013;24(12):2003–15. https://doi.org/10.1016/j.jnutbio.2013.07.002.CrossRefPubMed

64.

Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity. 2006;14(1):28–35. https://doi.org/10.1038/oby.2006.5.CrossRefPubMed

65.

Hoehn KL, Salmon AB, Hohnen-Behrens C, Turner N, Hoy AJ, Maghzal GJ, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA. 2009;106(42):17787–92. https://doi.org/10.1073/pnas.0902380106.CrossRefPubMedPubMedCentral

66.

Jiao P, Ma J, Feng B, Zhang H, Alan-Diehl J, Eugene-Chin Y, et al. FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKKβ pathways. Obesity. 2011;19(3):483–91. https://doi.org/10.1038/oby.2010.200.CrossRefPubMed

67.

Morigny P, Houssier M, Mouisel E, Langin D. Adipocyte lipolysis and insulin resistance. Biochimie. 2016;125:259–66. https://doi.org/10.1016/j.biochi.2015.10.024.CrossRefPubMed

68.

Drolet R, Richard C, Sniderman AD, Mailloux J, Fortier M, Huot C, et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes. 2008;32(2):283–91. https://doi.org/10.1038/sj.ijo.0803708.CrossRef

69.

Baldini F, Fabbri R, Eberhagen C, Voci A, Portincasa P, Zischka H, et al. Adipocyte hypertrophy parallels alterations of mitochondrial status in a cell model for adipose tissue dysfunction in obesity. Life Sci. 2021;265:118812. https://doi.org/10.1016/j.lfs.2020.118812.CrossRefPubMed

70.

Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. Diabetologia. 2000;43(12):1498–506. https://doi.org/10.1007/s001250051560.CrossRefPubMed

71.

Giordano A, Murano I, Mondini E, Perugini J, Smorlesi A, Severi I, et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J Lipid Res. 2013;54(9):2423–36. https://doi.org/10.1194/jlr.M038638.CrossRefPubMedPubMedCentral

72.

Verboven K, Wouters K, Gaens K, Hansen D, Bijnen M, Wetzels S, et al. Abdominal subcutaneous and visceral adipocyte size, lipolysis and inflammation relate to insulin resistance in male obese humans. Sci Rep. 2018;8(1):4677. https://doi.org/10.1038/s41598-018-22962-x.CrossRefPubMedPubMedCentral

73.

Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol-Endocrinol Metab. 2007;293(4):E1118–28. https://doi.org/10.1152/ajpendo.00435.2007.CrossRefPubMed

74.

Politis-Barber V, Brunetta HS, Paglialunga S, Petrick HL, Holloway GP. Long-term, high-fat feeding exacerbates short-term increases in adipose mitochondrial reactive oxygen species, without impairing mitochondrial respiration. Am J Physiol-Endocrinol Metab. 2020;319(2):E376–87.PubMedPubMedCentralCrossRef

75.

Lee YS, Kim J-w, Osborne O, Sasik R, Schenk S, Chen A, et al. Increased adipocyte O2 consumption triggers HIF-1α, causing inflammation and insulin resistance in obesity. Cell. 2014;157(6):1339–52.PubMedPubMedCentralCrossRef

76.

Tanaka M, Ikeda K, Suganami T, Komiya C, Ochi K, Shirakawa I, et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nat Commun. 2014;5(1):4982. https://doi.org/10.1038/ncomms5982.CrossRefPubMed

77.

Ji Y, Li M, Chang M, Liu R, Qiu J, Wang K, et al. Inflammation: roles in skeletal muscle atrophy. Antioxidants. 2022;11(9):1686.PubMedPubMedCentralCrossRef

78.

Mosser RE, Maulis MF, Moullé VS, Dunn JC, Carboneau BA, Arasi K, et al. High-fat diet-induced β-cell proliferation occurs prior to insulin resistance in C57Bl/6J male mice. Am J Physiol-Endocrinol Metab. 2015;308(7):E573–82.PubMedPubMedCentralCrossRef

79.

van Vliet S, Koh H-CE, Patterson BW, Yoshino M, LaForest R, Gropler RJ, et al. Obesity is associated with increased basal and postprandial β-cell insulin secretion even in the absence of insulin resistance. Diabetes. 2020;69(10):2112–9.PubMedPubMedCentralCrossRef

80.

Mir SU, George NM, Zahoor L, Harms R, Guinn Z, Sarvetnick NE. Inhibition of autophagic turnover in β-cells by fatty acids and glucose leads to apoptotic cell death. J Biol Chem. 2015;290(10):6071–85.PubMedCrossRef

81.

Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol. 2013;4:37.CrossRef

82.

Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133(2):496–506. https://doi.org/10.1053/j.gastro.2007.04.068.CrossRefPubMed

83.

Fu Z, R Gilbert E, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9(1):25–53.PubMedPubMedCentralCrossRef

84.

Miki A, Ricordi C, Sakuma Y, Yamamoto T, Misawa R, Mita A, et al. Divergent antioxidant capacity of human islet cell subsets: A potential cause of beta-cell vulnerability in diabetes and islet transplantation. PLoS ONE. 2018;13(5):e0196570. https://doi.org/10.1371/journal.pone.0196570.CrossRefPubMedPubMedCentral

85.

Gerber PA, Rutter GA. The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus. Antioxid Redox Signal. 2017;26(10):501–18.PubMedPubMedCentralCrossRef

86.

Hirata Y, Nomura K, Senga Y, Okada Y, Kobayashi K, Okamoto S, et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight. 2019;4(4):e124952. https://doi.org/10.1172/jci.insight.124952.CrossRefPubMedPubMedCentral

87.

Suzuki A, Yabu A, Nakamura H. Advanced glycation end products in musculoskeletal system and disorders. Methods. 2022;203:179–86. https://doi.org/10.1016/j.ymeth.2020.09.012.CrossRefPubMed

88.

Kashyap SR, Roman LJ, Lamont J, Masters BSS, Bajaj M, Suraamornkul S, et al. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab. 2005;90(2):1100–5. https://doi.org/10.1210/jc.2004-0745.CrossRefPubMed

89.

Jenkins HN, Rivera-Gonzalez O, Gibert Y, Speed JS. Endothelin-1 in the pathophysiology of obesity and insulin resistance. Obes Rev. 2020;21(12):e13086.PubMedPubMedCentralCrossRef

90.

Liu S-Y, Chen L-K, Jhong Y-T, Chen C-W, Hsiao L-E, Ku H-C, et al. Endothelin-1 impairs skeletal muscle myogenesis and development via ETB receptors and p38 MAPK signaling pathway. Clin Sci. 2024;138(12):711–23. https://doi.org/10.1042/cs20240341.CrossRef

91.

Banks NF, Rogers EM, Church DD, Ferrando AA, Jenkins ND. The contributory role of vascular health in age-related anabolic resistance. J Cachexia Sarcopenia Muscle. 2022;13(1):114–27. https://doi.org/10.1002/jcsm.12898.CrossRefPubMed

92.

Bleau C, Karelis AD, St-Pierre DH, Lamontagne L. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev. 2015;31(6):545–61. https://doi.org/10.1002/dmrr.2617.CrossRefPubMed

93.

Cox AJ, Zhang P, Bowden DW, Devereaux B, Davoren PM, Cripps AW, et al. Increased intestinal permeability as a risk factor for type 2 diabetes. Diabetes Metab. 2017;43(2):163–6. https://doi.org/10.1016/j.diabet.2016.09.004.CrossRefPubMed

94.

Teixeira TFS, Souza NCS, Chiarello PG, Franceschini SCC, Bressan J, Ferreira CLLF, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr. 2012;31(5):735–40. https://doi.org/10.1016/j.clnu.2012.02.009.CrossRefPubMed

95.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72. https://doi.org/10.2337/db06-1491.CrossRefPubMed

96.

Fang W-Y, Tseng Y-T, Lee T-Y, Fu Y-C, Chang W-H, Lo W-W, et al. Triptolide prevents LPS-induced skeletal muscle atrophy via inhibiting NF-κB/TNF-α and regulating protein synthesis/degradation pathway. Br J Pharmacol. 2021;178(15):2998–3016. https://doi.org/10.1111/bph.15472.CrossRefPubMed

97.

Scheithauer TP, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, Van Raalte DH, et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020;11:571731.PubMedPubMedCentralCrossRef

98.

Martin-Gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80(1):37–49.PubMedCrossRef

99.

Fragala MS, Kenny AM, Kuchel GA. Muscle quality in aging: a multi-dimensional approach to muscle functioning with applications for treatment. Sports Med. 2015;45:641–58.PubMedCrossRef

100.

Correa-de-Araujo R, Harris-Love MO, Miljkovic I, Fragala MS, Anthony BW, Manini TM. The need for standardized assessment of muscle quality in skeletal muscle function deficit and other aging-related muscle dysfunctions: a symposium report. Front Physiol. 2017;8:87. https://doi.org/10.3389/fphys.2017.00087.CrossRefPubMedPubMedCentral

101.

Abdulla H, Smith K, Atherton PJ, Idris I. Role of insulin in the regulation of human skeletal muscle protein synthesis and breakdown: a systematic review and meta-analysis. Diabetologia. 2016;59(1):44–55. https://doi.org/10.1007/s00125-015-3751-0.CrossRefPubMed

102.

Fujita S, Glynn EL, Timmerman KL, Rasmussen BB, Volpi E. Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism. Diabetologia. 2009;52(9):1889–98. https://doi.org/10.1007/s00125-009-1430-8.CrossRefPubMedPubMedCentral

103.

Timmerman KL, Lee JL, Dreyer HC, Dhanani S, Glynn EL, Fry CS, et al. Insulin stimulates human skeletal muscle protein synthesis via an indirect mechanism involving endothelial-dependent vasodilation and mammalian target of rapamycin complex 1 signaling. J Clin Endocrinol Metab. 2010;95(8):3848–57. https://doi.org/10.1210/jc.2009-2696.CrossRefPubMedPubMedCentral

104.

Aslesh T, Al-aghbari A, Yokota T. Assessing the role of aquaporin 4 in skeletal muscle function. Int J Mol Sci. 2023;24(2):1489.PubMedPubMedCentralCrossRef

105.

Chung SW, Kim J-Y, Yoon JP, Suh DW, Yeo WJ, Lee Y-S. Atrogin1-induced loss of aquaporin 4 in myocytes leads to skeletal muscle atrophy. Sci Rep. 2020;10(1):14189. https://doi.org/10.1038/s41598-020-71167-8.CrossRefPubMedPubMedCentral

106.

Khalid M, Alkaabi J, Khan MAB, Adem A. Insulin signal transduction perturbations in insulin resistance. Int J Mol Sci. 2021;22(16):8590.PubMedPubMedCentralCrossRef

107.

Luo J, Sobkiw CL, Hirshman MF, Logsdon MN, Li TQ, Goodyear LJ, et al. Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab. 2006;3(5):355–66. https://doi.org/10.1016/j.cmet.2006.04.003.CrossRefPubMed

108.

Hargett SR, Walker NN, Keller SR. Rab GAPs AS160 and Tbc1d1 play nonredundant roles in the regulation of glucose and energy homeostasis in mice. Am J Physiol-Endocrinol Metab. 2016;310(4):E276–88. https://doi.org/10.1152/ajpendo.00342.2015.CrossRefPubMed

109.

Sylow L, Tokarz VL, Richter EA, Klip A. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metab. 2021;33(4):758–80. https://doi.org/10.1016/j.cmet.2021.03.020.CrossRefPubMed

110.

Goul C, Peruzzo R, Zoncu R. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease. Nat Rev Mol Cell Biol. 2023;24(12):857–75. https://doi.org/10.1038/s41580-023-00641-8.CrossRefPubMed

111.

Mammucari C, Schiaffino S, Sandri M. Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy. 2008;4(4):524–6. https://doi.org/10.4161/auto.5905.CrossRefPubMed

112.

Jaiswal N, Gavin M, Loro E, Sostre-Colón J, Roberson PA, Uehara K, et al. AKT controls protein synthesis and oxidative metabolism via combined mTORC1 and FOXO1 signalling to govern muscle physiology. J Cachexia Sarcopenia Muscle. 2022;13(1):495–514. https://doi.org/10.1002/jcsm.12846.CrossRefPubMed

113.

Bodine SC, Baehr LM. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am J Physiol Endocrinol Metab. 2014;307(6):E469–84. https://doi.org/10.1152/ajpendo.00204.2014.CrossRefPubMedPubMedCentral

114.

Clavel S, Siffroi-Fernandez S, Coldefy AS, Boulukos K, Pisani DF, Dérijard B. Regulation of the intracellular localization of Foxo3a by stress-activated protein kinase signaling pathways in skeletal muscle cells. Mol Cell Biol. 2010;30(2):470–80.PubMedCrossRef

115.

Klotz L-O, Sánchez-Ramos C, Prieto-Arroyo I, Urbánek P, Steinbrenner H, Monsalve M. Redox regulation of FoxO transcription factors. Redox Biol. 2015;6:51–72. https://doi.org/10.1016/j.redox.2015.06.019.CrossRefPubMedPubMedCentral

116.

Schönfeld P, Wojtczak L. Short-and medium-chain fatty acids in energy metabolism: the cellular perspective. J Lipid Res. 2016;57(6):943–54.PubMedPubMedCentralCrossRef

117.

Sun J, Su Y, Chen J, Qin D, Xu Y, Chu H, et al. Differential roles of CD36 in regulating muscle insulin response depend on palmitic acid load. Biomedicines. 2023;11(3):729.PubMedPubMedCentralCrossRef

118.

Bonen A, Parolin ML, Steinberg GR, Calles-Escandon J, Tandon NN, Glatz JFC, et al. Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J. 2004;18(10):1144–6. https://doi.org/10.1096/fj.03-1065fje.CrossRefPubMed

119.

Clarke DC, Miskovic D, Han X-X, Calles-Escandon J, Glatz JFC, Luiken JJFP, et al. Overexpression of membrane-associated fatty acid binding protein (FABPpm) in vivo increases fatty acid sarcolemmal transport and metabolism. Physiol Genomics. 2004;17(1):31–7. https://doi.org/10.1152/physiolgenomics.00190.2003.CrossRefPubMed

120.

Glatz JFC, Luiken JJFP, Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev. 2010;90(1):367–417. https://doi.org/10.1152/physrev.00003.2009.CrossRefPubMed

121.

Roepstorff C, Wulff Helge J, Vistisen B, Kiens B. Studies of plasma membrane fatty acid-binding protein and other lipid-binding proteins in human skeletal muscle. Proc Nutr Soc. 2007;63(2):239–44. https://doi.org/10.1079/PNS2004332.CrossRef

122.

Kawaguchi M, Tamura Y, Kakehi S, Takeno K, Sakurai Y, Watanabe T, et al. Association between expression of FABPpm in skeletal muscle and insulin sensitivity in intramyocellular lipid-accumulated nonobese men. J Clin Endocrinol Metab. 2014;99(9):3343–52. https://doi.org/10.1210/jc.2014-1896.CrossRefPubMed

123.

Lundsgaard A-M, Fritzen AM, Kiens B. Molecular regulation of fatty acid oxidation in skeletal muscle during aerobic exercise. Trends Endocrinol Metab. 2018;29(1):18–30.PubMedCrossRef

124.

Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51(10):2944–50. https://doi.org/10.2337/diabetes.51.10.2944.CrossRefPubMed

125.

Pileggi CA, Parmar G, Harper ME. The lifecycle of skeletal muscle mitochondria in obesity. Obes Rev. 2021;22(5):e13164.PubMedCrossRef

126.

Timmers S, Schrauwen P, de Vogel J. Muscular diacylglycerol metabolism and insulin resistance. Physiol Behav. 2008;94(2):242–51.PubMedCrossRef

127.

Szendroedi J, Yoshimura T, Phielix E, Koliaki C, Marcucci M, Zhang D, et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc Natl Acad Sci USA. 2014;111(26):9597–602. https://doi.org/10.1073/pnas.1409229111.CrossRefPubMedPubMedCentral

128.

Jayasinghe SU, Tankeu AT, Amati F. Reassessing the role of diacylglycerols in insulin resistance. Trends Endocrinol Metab. 2019;30(9):618–35. https://doi.org/10.1016/j.tem.2019.06.005.CrossRefPubMed

129.

Gaspar RC, Lyu K, Hubbard BT, Leitner BP, Luukkonen PK, Hirabara SM, et al. Distinct subcellular localisation of intramyocellular lipids and reduced PKCε/PKCθ activity preserve muscle insulin sensitivity in exercise-trained mice. Diabetologia. 2023;66(3):567–78. https://doi.org/10.1007/s00125-022-05838-8.CrossRefPubMed

130.

Li Y, Soos TJ, Li X, Wu J, DeGennaro M, Sun X, et al. Protein kinase C θ inhibits insulin signaling by phosphorylating IRS1 at Ser1101. J Biol Chem. 2004;279(44):45304–7.PubMedCrossRef

131.

Jollet M, Tramontana F, Jiang LQ, Borg ML, Savikj M, Kuefner MS, et al. Diacylglycerol kinase delta overexpression improves glucose clearance and protects against the development of obesity. Metabolism. 2024;158:155939. https://doi.org/10.1016/j.metabol.2024.155939.CrossRefPubMed

132.

Wada Y, Sakiyama S, Sakai H, Sakane F. Myristic acid enhances diacylglycerol kinase δ-dependent glucose uptake in myotubes. Lipids. 2016;51:897–903.PubMedCrossRef

133.

Turpin-Nolan SM, Hammerschmidt P, Chen W, Jais A, Timper K, Awazawa M, et al. CerS1-derived C18: 0 ceramide in skeletal muscle promotes obesity-induced insulin resistance. Cell Rep. 2019;26(1):1-10. e7.PubMedCrossRef

134.

Bandet C, Tan-Chen S, Bourron O, Le Stunff H, Hajduch E. Sphingolipid metabolism: new insight into ceramide-induced lipotoxicity in muscle cells. Int J Mol Sci. 2019;20:479. https://doi.org/10.3390/ijms20030479.CrossRefPubMedPubMedCentral

135.

Bandet CL, Mahfouz R, Véret J, Sotiropoulos A, Poirier M, Giussani P, et al. Ceramide transporter CERT is involved in muscle insulin signaling defects under lipotoxic conditions. Diabetes. 2018;67(7):1258–71. https://doi.org/10.2337/db17-0901.CrossRefPubMed

136.

Powell DJ, Turban S, Gray A, Hajduch E, Hundal HS. Intracellular ceramide synthesis and protein kinase Czeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J. 2004;382(Pt 2):619–29. https://doi.org/10.1042/bj20040139.CrossRefPubMedPubMedCentral

137.

Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C. A role for protein phosphatase 2A–like activity, but not atypical protein kinase Cζ, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes. 2001;50(10):2210–8. https://doi.org/10.2337/diabetes.50.10.2210.CrossRefPubMed

138.

Hassan RH, de Sousa ACP, Mahfouz R, Hainault I, Blachnio-Zabielska A, Bourron O, et al. Sustained action of ceramide on the insulin signaling pathway in muscle cells: implication of the double-stranded RNA-activated protein kinase. J Biol Chem. 2016;291(6):3019–29.CrossRef

139.

Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, Albert V, Edom-Vovard F, Vidal-Puig A, et al. Human adipocytes induce inflammation and atrophy in muscle cells during obesity. Diabetes. 2015;64(9):3121–34.PubMedCrossRef

140.

Chen Z-T, Weng Z-X, Lin JD, Meng Z-X. Myokines: metabolic regulation in obesity and type 2 diabetes. Life Metab. 2024;3(3):loae006. https://doi.org/10.1093/lifemeta/loae006.CrossRefPubMedPubMedCentral

141.

Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K. The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens. 2000;18(11):1605–10. https://doi.org/10.1097/00004872-200018110-00011.CrossRefPubMed

142.

Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 1997;389(6651):610–4. https://doi.org/10.1038/39335.CrossRefPubMed

143.

Fritsche L, Neukamm SS, Lehmann R, Kremmer E, Hennige AM, Hunder-Gugel A, et al. Insulin-induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR: studies on the function of Ser675 and Ser907. Am J Physiol-Endocrinol Metab. 2011;300(5):E824–36. https://doi.org/10.1152/ajpendo.00409.2010.CrossRefPubMed

144.

Solinas G, Karin M. JNK1 and IKKβ: molecular links between obesity and metabolic dysfunction. FASEB J. 2010;24(8):2596–611.PubMedCrossRef

145.

Thoma A, Lightfoot AP. NF-kB and inflammatory cytokine signalling: role in skeletal muscle atrophy. Muscle Atrophy. 2018. 267–79. https://doi.org/10.1007/978-981-13-1435-3_12.

146.

Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54(10):2939–45. https://doi.org/10.2337/diabetes.54.10.2939.CrossRefPubMed

147.

de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem. 2004;279(17):17070–8. https://doi.org/10.1074/jbc.M312021200.CrossRefPubMed

148.

Li P, Oh DY, Bandyopadhyay G, Lagakos WS, Talukdar S, Osborn O, et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015;21(3):239–47. https://doi.org/10.1038/nm.3800.CrossRefPubMedPubMedCentral

149.

Luo G, Hershko DD, Robb BW, Wray CJ, Hasselgren P-O. IL-1β stimulates IL-6 production in cultured skeletal muscle cells through activation of MAP kinase signaling pathway and NF-κB. Am J Physiol-Regul Integr Comp Physiol. 2003;284(5):R1249–54. https://doi.org/10.1152/ajpregu.00490.2002.CrossRefPubMed

150.

Ghanbari M, Momen Maragheh S, Aghazadeh A, Mehrjuyan SR, Hussen BM, Abdoli Shadbad M, et al. Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies. Int Immunopharmacol. 2021;96:107765. https://doi.org/10.1016/j.intimp.2021.107765.CrossRefPubMed

151.

Gao D, Madi M, Ding C, Fok M, Steele T, Ford C, et al. Interleukin-1β mediates macrophage-induced impairment of insulin signaling in human primary adipocytes. Am J Physiol-Endocrinol Metab. 2014;307(3):E289–304. https://doi.org/10.1152/ajpendo.00430.2013.CrossRefPubMedPubMedCentral

152.

Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, et al. Interleukin-1–receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517–26.PubMedCrossRef

153.

Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid–induced insulin resistance. J Clin Investig. 2006;116(11):3015–25.PubMedPubMedCentralCrossRef

154.

Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003;44(3):479–86.PubMedCrossRef

155.

Hwang DH, Kim J-A, Lee JY. Mechanisms for the activation of Toll-like receptor 2/4 by saturated fatty acids and inhibition by docosahexaenoic acid. Eur J Pharmacol. 2016;785:24–35. https://doi.org/10.1016/j.ejphar.2016.04.024.CrossRefPubMedPubMedCentral

156.

Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT-H, et al. Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12(5):408–15. https://doi.org/10.1038/ni.2022.CrossRefPubMedPubMedCentral

157.

Russell-Guzmán J, Américo-Da Silva L, Cadagan C, Maturana M, Palomero J, Estrada M, et al. Activation of the ROS/TXNIP/NLRP3 pathway disrupts insulin-dependent glucose uptake in skeletal muscle of insulin-resistant obese mice. Free Radical Biol Med. 2024;222:187–98. https://doi.org/10.1016/j.freeradbiomed.2024.06.011.CrossRef

158.

Américo-Da-Silva L, Aguilera J, Quinteros-Waltemath O, Sánchez-Aguilera P, Russell J, Cadagan C, et al. Activation of the NLRP3 inflammasome increases the IL-1β level and decreases GLUT4 translocation in skeletal muscle during insulin resistance. Int J Mol Sci. 2021;22(19):10212.PubMedPubMedCentralCrossRef

159.

Eggelbusch M, Shi A, Broeksma BC, Vázquez-Cruz M, Soares MN, de Wit GMJ, et al. The NLRP3 inflammasome contributes to inflammation-induced morphological and metabolic alterations in skeletal muscle. J Cachexia Sarcopenia Muscle. 2022;13(6):3048–61. https://doi.org/10.1002/jcsm.13062.CrossRefPubMedPubMedCentral

160.

Grzelkowska-Kowalczyk K, Wieteska-Skrzeczyńska W. Treatment with IFN-γ prevents insulin-dependent PKB, p70S6k phosphorylation and protein synthesis in mouse C2C12 myogenic cells. Cell Biol Int. 2010;34(1):117–24. https://doi.org/10.1042/CBI20090135.CrossRef

161.

Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.PubMedPubMedCentralCrossRef

162.

Zhang L, Chen Z, Wang Y, Tweardy DJ, Mitch WE. Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40. Am J Physiol Endocrinol Metab. 2020;318(5):E625–35. https://doi.org/10.1152/ajpendo.00480.2019.CrossRefPubMedPubMedCentral

163.

Abid H, Ryan ZC, Delmotte P, Sieck GC, Lanza IR. Extramyocellular interleukin-6 influences skeletal muscle mitochondrial physiology through canonical JAK/STAT signaling pathways. FASEB J. 2020;34(11):14458–72. https://doi.org/10.1096/fj.202000965RR.CrossRefPubMed

164.

Wu CL, Kandarian SC, Jackman RW. Identification of genes that elicit disuse muscle atrophy via the transcription factors p50 and Bcl-3. PLoS One. 2011;6(1):e16171. https://doi.org/10.1371/journal.pone.0016171.CrossRefPubMedPubMedCentral

165.

Cai D, Frantz JD, Tawa NE, Melendez PA, Oh B-C, Lidov HGW, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285–98. https://doi.org/10.1016/j.cell.2004.09.027.CrossRefPubMed

166.

Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J : Off Publ Fed Am Soc Exp Biol. 2005;19(3):362–70. https://doi.org/10.1096/fj.04-2364com.CrossRef

167.

Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol-Endocrinol Metab. 2012;303(3):E410–21. https://doi.org/10.1152/ajpendo.00039.2012.CrossRefPubMedPubMedCentral

168.

Zhang L, Pan J, Dong Y, Tweardy DJ, Dong Y, Garibotto G, et al. Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 2013;18(3):368–79. https://doi.org/10.1016/j.cmet.2013.07.012.CrossRefPubMedPubMedCentral

169.

Chomentowski P, Coen PM, Radiková Z, Goodpaster BH, Toledo FG. Skeletal muscle mitochondria in insulin resistance: differences in intermyofibrillar versus subsarcolemmal subpopulations and relationship to metabolic flexibility. J Clin Endocrinol Metab. 2011;96(2):494–503. https://doi.org/10.1210/jc.2010-0822.CrossRefPubMed

170.

Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA. 2003;100(14):8466–71. https://doi.org/10.1073/pnas.1032913100.CrossRefPubMedPubMedCentral

171.

Heilbronn LK, Gan SK, Turner N, Campbell LV, Chisholm DJ. Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects. J Clin Endocrinol Metab. 2007;92(4):1467–73. https://doi.org/10.1210/jc.2006-2210.CrossRefPubMed

172.

Russell AP, Feilchenfeldt J, Schreiber S, Praz M, Crettenand A, Gobelet C, et al. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes. 2003;52(12):2874–81. https://doi.org/10.2337/diabetes.52.12.2874.CrossRefPubMed

173.

Boyle KE, Canham JP, Consitt LA, Zheng D, Koves TR, Gavin TP, et al. A high-fat diet elicits differential responses in genes coordinating oxidative metabolism in skeletal muscle of lean and obese individuals. J Clin Endocrinol Metab. 2011;96(3):775–81. https://doi.org/10.1210/jc.2010-2253.CrossRefPubMed

174.

Richardson DK, Kashyap S, Bajaj M, Cusi K, Mandarino SJ, Finlayson J, et al. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem. 2005;280(11):10290–7. https://doi.org/10.1074/jbc.M408985200.CrossRefPubMed

175.

Kong S, Cai B, Nie Q. PGC-1α affects skeletal muscle and adipose tissue development by regulating mitochondrial biogenesis. Mol Genet Genomics. 2022;297(3):621–33. https://doi.org/10.1007/s00438-022-01878-2.CrossRefPubMed

176.

Figueroa-Toledo AM, Gutiérrez-Pino J, Carriel-Nesvara A, Marchese-Bittencourt M, Zbinden-Foncea H, Castro-Sepúlveda M. BMAL1 and CLOCK proteins exhibit differential association with mitochondrial dynamics, protein synthesis pathways and muscle strength in human muscle. J Physiol. 2024. https://doi.org/10.1113/jp285955.CrossRefPubMed

177.

Wefers J, Connell NJ, Fealy CE, Andriessen C, de Wit V, van Moorsel D, et al. Day-night rhythm of skeletal muscle metabolism is disturbed in older, metabolically compromised individuals. Mol Metab. 2020;41:101050. https://doi.org/10.1016/j.molmet.2020.101050.CrossRefPubMedPubMedCentral

178.

Houzelle A, Jörgensen JA, Schaart G, Daemen S, van Polanen N, Fealy CE, et al. Human skeletal muscle mitochondrial dynamics in relation to oxidative capacity and insulin sensitivity. Diabetologia. 2021;64(2):424–36. https://doi.org/10.1007/s00125-020-05335-w.CrossRefPubMed

179.

Gemmink A, Daemen S, Wefers J, Hansen J, van Moorsel D, Astuti P, et al. Twenty-four hour rhythmicity in mitochondrial network connectivity and mitochondrial respiration; a study in human skeletal muscle biopsies of young lean and older individuals with obesity. Mol Metab. 2023;72:101727. https://doi.org/10.1016/j.molmet.2023.101727.CrossRefPubMedPubMedCentral

180.

Gabriel BM, Altıntaş A, Smith JAB, Sardon-Puig L, Zhang X, Basse AL, et al. Disrupted circadian oscillations in type 2 diabetes are linked to altered rhythmic mitochondrial metabolism in skeletal muscle. Sci Adv. 2021;7(43):eabi9654. https://doi.org/10.1126/sciadv.abi9654.CrossRefPubMedPubMedCentral

181.

Liu R, Jin P, Yu L, Wang Y, Han L, Shi T, et al. Impaired mitochondrial dynamics and bioenergetics in diabetic skeletal muscle. PloS one. 2014;9(3):e92810.PubMedPubMedCentralCrossRef

182.

Jheng H-F, Tsai P-J, Guo S-M, Kuo L-H, Chang C-S, Su I-J, et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol Cell Biol. 2012;32(2):309–19. https://doi.org/10.1128/MCB.05603-11.CrossRefPubMedPubMedCentral

183.

Dai W, Jiang L. Dysregulated mitochondrial dynamics and metabolism in obesity, diabetes, and cancer. Front Endocrinol. 2019;10:570.CrossRef

184.

Kugler BA, Labaf M, Nguyen P, Lin N, Houmard JA, Zarringhalam K, et al. The loss of Drp1 improves skeletal muscle insulin action in primary myotubes derived from humans with severe obesity. FASEB J. 2022;36(S1):R4873. https://doi.org/10.1096/fasebj.2022.36.S1.R4873.CrossRef

185.

Axelrod CL, Fealy CE, Erickson ML, Davuluri G, Fujioka H, Dantas WS, et al. Lipids activate skeletal muscle mitochondrial fission and quality control networks to induce insulin resistance in humans. Metabolism. 2021;121:154803.PubMedPubMedCentralCrossRef

186.

Smith ME, Tippetts TS, Brassfield ES, Tucker BJ, Ockey A, Swensen AC, et al. Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscle. Biochem J. 2013;456(3):427–39.PubMedCrossRef

187.

Bikman BT. Mitochondrial fission is necessary for ceramide-induced metabolic disruption. FASEB J. 2016;30(S1):307.5-.5. https://doi.org/10.1096/fasebj.30.1_supplement.307.5.CrossRef

188.

Perreault L, Newsom SA, Strauss A, Kerege A, Kahn DE, Harrison KA, et al. Intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle. JCI Insight. 2018;3(3):e96805. https://doi.org/10.1172/jci.insight.96805.CrossRefPubMedPubMedCentral

189.

Diaz-Vegas A, Madsen S, Cooke KC, Carroll L, Khor JX, Turner N, et al. Mitochondrial electron transport chain, ceramide, and coenzyme Q are linked in a pathway that drives insulin resistance in skeletal muscle. Elife. 2023;12:RP87340.PubMedPubMedCentralCrossRef

190.

Finocchietto P, Perez H, Blanco G, Miksztowicz V, Marotte C, Morales C, et al. Inhibition of mitochondrial fission by Drp-1 blockade by short-term leptin and Mdivi-1 treatment improves white adipose tissue abnormalities in obesity and diabetes. Pharmacol Res. 2022;178:106028. https://doi.org/10.1016/j.phrs.2021.106028.CrossRefPubMed

191.

Liesa M, Palacín M, Zorzano A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev. 2009;89(3):799–845.PubMedCrossRef

192.

Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 2003;278(19):17190–7. https://doi.org/10.1074/jbc.M212754200.CrossRefPubMed

193.

Bach D, Naon D, Pich S, Soriano FX, Vega N, Rieusset J, et al. Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. Diabetes. 2005;54(9):2685–93. https://doi.org/10.2337/diabetes.54.9.2685.CrossRefPubMed

194.

Fealy CE, Mulya A, Axelrod CL, Kirwan JP. Mitochondrial dynamics in skeletal muscle insulin resistance and type 2 diabetes. Transl Res. 2018;202:69–82.PubMedCrossRef

195.

Pereira RO, Tadinada SM, Zasadny FM, Oliveira KJ, Pires KMP, Olvera A, et al. OPA1 deficiency promotes secretion of FGF21 from muscle that prevents obesity and insulin resistance. EMBO J. 2017;36(14):2126–45. https://doi.org/10.15252/embj.201696179.CrossRefPubMedPubMedCentral

196.

Favaro G, Romanello V, Varanita T, Andrea Desbats M, Morbidoni V, Tezze C, et al. DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass. Nat Commun. 2019;10(1):2576. https://doi.org/10.1038/s41467-019-10226-9.CrossRefPubMedPubMedCentral

197.

Nisr RB, Shah DS, Ganley IG, Hundal HS. Proinflammatory NFkB signalling promotes mitochondrial dysfunction in skeletal muscle in response to cellular fuel overloading. Cell Mol Life Sci. 2019;76:4887–904.PubMedPubMedCentralCrossRef

198.

Di Meo S, Iossa S, Venditti P. Skeletal muscle insulin resistance: role of mitochondria and other ROS sources. J Endocrinol. 2017;233(1):R15–42.PubMedCrossRef

199.

Lin H-Y, Weng S-W, Chang Y-H, Su Y-J, Chang C-M, Tsai C-J, et al. The causal role of mitochondrial dynamics in regulating insulin resistance in diabetes: link through mitochondrial reactive oxygen species. Oxid Med Cell Longev. 2018;2018(1):7514383. https://doi.org/10.1155/2018/7514383.CrossRefPubMedPubMedCentral

200.

Fan X, Hussien R, Brooks GA. H2O2-induced mitochondrial fragmentation in C2C12 myocytes. Free Radical Biol Med. 2010;49(11):1646–54. https://doi.org/10.1016/j.freeradbiomed.2010.08.024.CrossRef

201.

Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009;119(3):573–81. https://doi.org/10.1172/jci37048.CrossRefPubMedPubMedCentral

202.

Lark DS, Kang L, Lustig ME, Bonner JS, James FD, Neufer PD, et al. Enhanced mitochondrial superoxide scavenging does not improve muscle insulin action in the high fat-fed mouse. PLoS One. 2015;10(5):e0126732. https://doi.org/10.1371/journal.pone.0126732.CrossRefPubMedPubMedCentral

203.

Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440(7086):944–8. https://doi.org/10.1038/nature04634.CrossRefPubMed

204.

Chen L, Na R, Gu M, Salmon AB, Liu Y, Liang H, et al. Reduction of mitochondrial H2O2 by overexpressing peroxiredoxin 3 improves glucose tolerance in mice. Aging Cell. 2008;7(6):866–78. https://doi.org/10.1111/j.1474-9726.2008.00432.x.CrossRefPubMed

205.

Boden MJ, Brandon AE, Tid-Ang JD, Preston E, Wilks D, Stuart E, et al. Overexpression of manganese superoxide dismutase ameliorates high-fat diet-induced insulin resistance in rat skeletal muscle. Am J Physiol Endocrinol Metab. 2012;303(6):E798-805. https://doi.org/10.1152/ajpendo.00577.2011.CrossRefPubMedPubMedCentral

206.

Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem. 2000;275(12):9047–54.PubMedCrossRef

207.

Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci USA. 2006;103(28):10741–6. https://doi.org/10.1073/pnas.0603509103.CrossRefPubMedPubMedCentral

208.

Fujishiro M, Gotoh Y, Katagiri H, Sakoda H, Ogihara T, Anai M, et al. MKK6/3 and p38 MAPK pathway activation is not necessary for insulin-induced glucose uptake but regulates glucose transporter expression. J Biol Chem. 2001;276(23):19800–6.PubMedCrossRef

209.

Archuleta TL, Lemieux AM, Saengsirisuwan V, Teachey MK, Lindborg KA, Kim JS, et al. Oxidant stress-induced loss of IRS-1 and IRS-2 proteins in rat skeletal muscle: Role of p38 MAPK. Free Radical Biol Med. 2009;47(10):1486–93. https://doi.org/10.1016/j.freeradbiomed.2009.08.014.CrossRef

210.

Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM-E, Clark SE, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem. 2006;281(46):35137–46.PubMedCrossRef

211.

Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-κB activation via NADPH oxidase. Am J Physiol-Endocrinol Metab. 2008;294(2):E345–51. https://doi.org/10.1152/ajpendo.00456.2007.CrossRefPubMed

212.

Pillon NJ, Croze ML, Vella RE, Soulère L, Lagarde M, Soulage CO. The lipid peroxidation by-product 4-hydroxy-2-nonenal (4-HNE) induces insulin resistance in skeletal muscle through both carbonyl and oxidative stress. Endocrinology. 2012;153(5):2099–111. https://doi.org/10.1210/en.2011-1957.CrossRefPubMed

213.

Lee H, Ha TY, Jung CH, Nirmala FS, Park S-Y, Huh YH, et al. Mitochondrial dysfunction in skeletal muscle contributes to the development of acute insulin resistance in mice. J Cachexia Sarcopenia Muscle. 2021;12(6):1925–39. https://doi.org/10.1002/jcsm.12794.CrossRefPubMedPubMedCentral

214.

Tsilingiris D, Tzeravini E, Koliaki C, Dalamaga M, Kokkinos A. The role of mitochondrial adaptation and metabolic flexibility in the pathophysiology of obesity and insulin resistance: an updated overview. Curr Obes Rep. 2021;10(3):191–213. https://doi.org/10.1007/s13679-021-00434-0.CrossRefPubMed

215.

Schiaffino S. Fibre types in skeletal muscle: a personal account. Acta Physiol (Oxf). 2010;199(4):451–63. https://doi.org/10.1111/j.1748-1716.2010.02130.x.CrossRefPubMed

216.

Stuart CA, McCurry MP, Marino A, South MA, Howell MEA, Layne AS, et al. Slow-twitch fiber proportion in skeletal muscle correlates with insulin responsiveness. J Clin Endocrinol Metab. 2013;98(5):2027–36. https://doi.org/10.1210/jc.2012-3876.CrossRefPubMedPubMedCentral

217.

Albers PH, Pedersen AJT, Birk JB, Kristensen DE, Vind BF, Baba O, et al. Human muscle fiber type-specific insulin signaling: impact of obesity and type 2 diabetes. Diabetes. 2014;64(2):485–97. https://doi.org/10.2337/db14-0590.CrossRefPubMed

218.

Daugaard JR, Nielsen JN, Kristiansen S, Andersen JL, Hargreaves M, Richter EA. Fiber type-specific expression of GLUT4 in human skeletal muscle: influence of exercise training. Diabetes. 2000;49(7):1092–5. https://doi.org/10.2337/diabetes.49.7.1092.CrossRefPubMed

219.

Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev. 2011;91(4):1447–531. https://doi.org/10.1152/physrev.00031.2010.CrossRefPubMed

220.

Damer A, El Meniawy S, McPherson R, Wells G, Harper ME, Dent R. Association of muscle fiber type with measures of obesity: A systematic review. Obes Rev : Off J Int Assoc Study Obes. 2022;23(7):e13444. https://doi.org/10.1111/obr.13444.CrossRef

221.

Lin J, Wu H, Tarr PT, Zhang C-Y, Wu Z, Boss O, et al. Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres. Nature. 2002;418(6899):797–801.PubMedCrossRef

222.

Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci USA. 2003;100(12):7111–6. https://doi.org/10.1073/pnas.1232352100.CrossRefPubMedPubMedCentral

223.

Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, et al. Peroxisome proliferator-activated receptor δ controls muscle development and oxydative capability. FASEB J. 2003;17(15):2299–301. https://doi.org/10.1096/fj.03-0269fje.CrossRefPubMed

224.

Wang Y-X, Zhang C-L, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, et al. Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol. 2004;2(10):e294. https://doi.org/10.1371/journal.pbio.0020294.CrossRefPubMedPubMedCentral

225.

Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1. Nature. 2010;464(7293):1313–9.PubMedCrossRef

226.

Zhou Q, Gu Y, Lang H, Wang X, Chen K, Gong X, et al. Dihydromyricetin prevents obesity-induced slow-twitch-fiber reduction partially via FLCN/FNIP1/AMPK pathway. Biochim Biophys Acta. 2017;1863(6):1282–91. https://doi.org/10.1016/j.bbadis.2017.03.019.CrossRef

227.

Hu M-M, Zheng W-Y, Cheng M-H, Song Z-Y, Shaukat H, Atta M, et al. Sesamol reverses myofiber-type conversion in obese states via activating the SIRT1/AMPK signal pathway. J Agric Food Chem. 2022;70(7):2253–64.PubMedCrossRef

228.

Jiang Q, Cheng X, Cui Y, Xia Q, Yan X, Zhang M, et al. Resveratrol regulates skeletal muscle fibers switching through the AdipoR1-AMPK-PGC-1α pathway. Food Funct. 2019;10(6):3334–43.PubMedCrossRef

229.

Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 1998;12(16):2499–509.PubMedPubMedCentralCrossRef

230.

Eshima H. Influence of obesity and type 2 diabetes on calcium handling by skeletal muscle: spotlight on the sarcoplasmic reticulum and mitochondria. Front Physiol. 2021;12:758316.PubMedPubMedCentralCrossRef

231.

Bottinelli R, Canepari M, Pellegrino MA, Reggiani C. Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. J Physiol. 1996;495((Pt 2)(Pt 2)):573–86. https://doi.org/10.1113/jphysiol.1996.sp021617.CrossRefPubMedPubMedCentral

232.

Straight CR, Toth MJ, Miller MS. Current perspectives on obesity and skeletal muscle contractile function in older adults. J Appl Physiol (Bethesda, Md : 1985). 2021;130(1):10–6. https://doi.org/10.1152/japplphysiol.00739.2020.CrossRef

233.

Twarda-Clapa A, Olczak A, Białkowska AM, Koziołkiewicz M. Advanced glycation end-products (AGEs): Formation, chemistry, classification, receptors, and diseases related to AGEs. Cells. 2022;11(8):1312.PubMedPubMedCentralCrossRef

234.

Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules. 2022;12(4):542.PubMedPubMedCentralCrossRef

235.

Peeters SA, Engelen L, Buijs J, Theilade S, Rossing P, Schalkwijk CG, et al. Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes. J Diabetes Complicat. 2018;32(3):325–9. https://doi.org/10.1016/j.jdiacomp.2017.12.011.CrossRef

236.

Egawa T, Tsuda S, Goto A, Ohno Y, Yokoyama S, Goto K, et al. Potential involvement of dietary advanced glycation end products in impairment of skeletal muscle growth and muscle contractile function in mice. Br J Nutr. 2017;117(1):21–9. https://doi.org/10.1017/S0007114516004591.CrossRefPubMed

237.

Ahmad K, Lee EJ, Moon JS, Park S-Y, Choi I. Multifaceted interweaving between extracellular matrix, insulin resistance, and skeletal muscle. Cells. 2018;7(10):148.PubMedPubMedCentralCrossRef

238.

Riuzzi F, Sorci G, Sagheddu R, Chiappalupi S, Salvadori L, Donato R. RAGE in the pathophysiology of skeletal muscle. J Cachexia Sarcopenia Muscle. 2018;9(7):1213–34.PubMedPubMedCentralCrossRef

239.

Miranda ER, Mey JT, Blackburn BK, Chaves AB, Fuller KNZ, Perkins RK, et al. Soluble RAGE and skeletal muscle tissue RAGE expression profiles in lean and obese young adults across differential aerobic exercise intensities. J Appl Physiol (Bethesda, Md : 1985). 2023;135(4):849–62. https://doi.org/10.1152/japplphysiol.00748.2022.CrossRef

240.

Chiu CY, Yang RS, Sheu ML, Chan DC, Yang TH, Tsai KS, et al. Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated, AMPK-down-regulated, Akt pathway. J Pathol. 2016;238(3):470–82.PubMedCrossRef

241.

Wautier M-P, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier J-L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol-Endocrinol Metab. 2001;280(5):E685–94. https://doi.org/10.1152/ajpendo.2001.280.5.E685.CrossRefPubMed

242.

Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol. 2009;20(4):742–52. https://doi.org/10.1681/asn.2008050514.CrossRefPubMedPubMedCentral

243.

Egawa T, Ogawa T, Yokokawa T, Kido K, Iyama R, Zhao H, et al. Glycative stress inhibits hypertrophy and impairs cell membrane integrity in overloaded mouse skeletal muscle. J Cachexia Sarcopenia Muscle. 2024;15(3):883–96. https://doi.org/10.1002/jcsm.13444.CrossRefPubMedPubMedCentral

244.

Du H, Ma Y, Wang X, Zhang Y, Zhu L, Shi S, et al. Advanced glycation end products induce skeletal muscle atrophy and insulin resistance via activating ROS-mediated ER stress PERK/FOXO1 signaling. Am J Physiol-Endocrinol Metab. 2023;324(3):E279–87.PubMedCrossRef

245.

Miranda ER, Somal VS, Mey JT, Blackburn BK, Wang E, Farabi S, et al. Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes. Am J Physiol-Endocrinol Metab. 2017;313(6):E631–40. https://doi.org/10.1152/ajpendo.00146.2017.CrossRefPubMedPubMedCentral

246.

Cid-Díaz T, Leal-López S, Fernández-Barreiro F, González-Sánchez J, Santos-Zas I, Andrade-Bulos LJ, et al. Obestatin signalling counteracts glucocorticoid-induced skeletal muscle atrophy via NEDD4/KLF15 axis. J Cachexia Sarcopenia Muscle. 2021;12(2):493–505. https://doi.org/10.1002/jcsm.12677.CrossRefPubMedPubMedCentral

247.

Lorenzo I, Serra-Prat M, Yébenes JC. The role of water homeostasis in muscle function and frailty: a review. Nutrients. 2019;11(8):1857.PubMedPubMedCentralCrossRef

248.

Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(10):545–55. https://doi.org/10.1038/s41574-020-0381-5.CrossRefPubMed

249.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.CrossRef

250.

Kanaley JA, Colberg SR, Corcoran MH, Malin SK, Rodriguez NR, Crespo CJ, et al. Exercise/physical activity in individuals with type 2 diabetes: a consensus statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2022;54(2):353–68. https://doi.org/10.1249/mss.0000000000002800.CrossRefPubMedPubMedCentral

251.

Phillips JA. Dietary guidelines for Americans, 2020–2025. Work Health Saf. 2021;69(8):395.CrossRef

252.

Thyfault JP, Bergouignan A. Exercise and metabolic health: beyond skeletal muscle. Diabetologia. 2020;63(8):1464–74. https://doi.org/10.1007/s00125-020-05177-6.CrossRefPubMedPubMedCentral

253.

McGee SL, Hargreaves M. Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefit. Nat Rev Endocrinol. 2020;16(9):495–505.PubMedCrossRef

254.

Egan B, Sharples AP. Molecular responses to acute exercise and their relevance for adaptations in skeletal muscle to exercise training. Physiol Rev. 2023;103(3):2057–170.PubMedCrossRef

255.

Richter EA. Is GLUT4 translocation the answer to exercise-stimulated muscle glucose uptake? Am J Physiol-Endocrinol Metab. 2021;320(2):E240–3. https://doi.org/10.1152/ajpendo.00503.2020.CrossRefPubMed

256.

Plotkin DL, Roberts MD, Haun CT, Schoenfeld BJ. Muscle fiber type transitions with exercise training: shifting perspectives. Sports. 2021;9(9):127.PubMedPubMedCentralCrossRef

257.

Safdar A, Little JP, Stokl AJ, Hettinga BP, Akhtar M, Tarnopolsky MA. Exercise increases mitochondrial PGC-1α content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis. J Biol Chem. 2011;286(12):10605–17.PubMedPubMedCentralCrossRef

258.

Wackerhage H, Schoenfeld BJ, Hamilton DL, Lehti M, Hulmi JJ. Stimuli and sensors that initiate skeletal muscle hypertrophy following resistance exercise. J Appl Physiol. 2019;126(1):30–43. https://doi.org/10.1152/japplphysiol.00685.2018.CrossRefPubMed

259.

Kistner TM, Pedersen BK, Lieberman DE. Interleukin 6 as an energy allocator in muscle tissue. Nat Metab. 2022;4(2):170–9. https://doi.org/10.1038/s42255-022-00538-4.CrossRefPubMed

260.

Pérez-Castillo IM, Sabag-Daigle A, López-Chicharro J, Mihic N, Rueda R, Bouzamondo H. The athlete gut microbiota: state of the art and practical guidance. Benefic Microbes. 2024;1(aop):1–30.

Podcast | Sexual health in older age

Springer Medicine

Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved

Abstract

Elevate your expertise in aplastic anemia (Link opens in a new window)

Keynote series | Spotlight on menopause